Cipla says top 50 drugs in development could bring in $30B

Indian drugmaker Cipla said it currently has 200 drugs in development and that the top 50 of those drugs have the potential to earn the company more than $30 billion. The Mumbai-based company also said it plans to expand its North American market share to 25% by 2020 and plans to devote more resources to R&D for that specific market. It also plans to seek more generics approvals there, according to a report in the Business Standard. More from FiercePharmaAsia

Suggested Articles

A TGen-led research team found that increased activity of the gene AEBP1 drives severe liver fibrosis in nonalcoholic steatohepatitis.

Days after announcing its R&D chief was stepping down, Gilead announced it will be buying a few of Novartis’ unwanted early-stage infection assets.

Mallinckrodt is teaming up with Silence Therapeutics to develop an RNAi program aimed at a group of proteins that play a part in promoting inflammation.